Nuvation Bio
NUVB
161 hedge funds and large institutions have $365M invested in Nuvation Bio in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 53 reducing their positions, and 18 closing their positions.
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
2.65% more ownership
Funds ownership: 58.75% → 61.4% (+2.6%)
1% more funds holding
Funds holding: 160 → 161 (+1)
0% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 53
31% less capital invested
Capital invested by funds: $526M → $365M (-$161M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
99% less call options, than puts
Call options by funds: $10K | Put options by funds: $899K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$7.69M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$5.58M |
| 4 |
Millennium Management
New York
|
+$2.95M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$2.97M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.46M |
| 3 |
Goldman Sachs
New York
|
-$2.29M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.23M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RS
176
R Squared
Central,
Hong Kong
| – | -$798 | -300 | Closed |
|
|
AAP
177
Arax Advisory Partners
Denver,
Colorado
| – | -$623 | -234 | Closed |
|
|
C
178
Covestor
London,
United Kingdom
| – | +$2 | +1 | +3% |
|
179
Bessemer Group
Woodbridge,
New Jersey
| – | +$278 | +122 | New |
|
NUVB Hedge Fund Activity: Q1 2025 in Review
161 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q1 2025, worth a combined $365M — down 31% from $526M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NUVB positions and 18 closed out — a net gain of 4 holders — while 53 added to existing stakes and 53 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.1M. The largest seller was Octagon Capital Advisors, cutting an estimated $2.97M.
- 161 institutional investors held Nuvation Bio (NUVB) as of Q1 2025, up from 160 in Q4 2024.
- Funds reported $365M of Nuvation Bio stock for Q1 2025, down 31% quarter-over-quarter.
- 22 funds opened new Nuvation Bio positions in Q1 2025 and 18 closed out, a net change of +4 holders.
- The largest Nuvation Bio buyer in Q1 2025 was Fidelity Investments, an estimated $12.1M added.
- The largest Nuvation Bio seller in Q1 2025 was Octagon Capital Advisors, an estimated $2.97M sold.
Based on aggregated 13F filings for Q1 2025.